Anne Vanlent, Director at Trevi Therapeutics, Inc. (TRVI), bought 25,983 shares at $10.00 ($50K) on 2019-05-09, disclosed to the SEC on 2019-05-13.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 20,983 | $0 | 0.0% |
| 2 | $10.00 | 5,000 | $50K | 100.0% |
| Total | $1.92 avg | 25,983 | $50K | 100% |
| Filing → |
| IART | SELL | 2011-01-14 | $250K | — | Filing → |
| PPCO | SELL | 2008-11-10 | $7K | — | Filing → |